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improving quality of life over extending life. ConClusions: Advanced NSCLC is 
known to impact many domains of patients’ lives. This study demonstrates that 
emotional impact and time taken undergoing treatment may be undervalued by 
commonly employed HRQoL metrics in clinical trials. Future clinical trials of new 
lung cancer treatments should include assessment of these concepts. Ultimately, 
HRQoL instruments should be identified/developed that satisfactorily capture all 
factors deemed important by patients in order to fully reflect impact of new treat-
ments on patients’ lives.
PCN221
PrefereNCe eliCitatioN oN BeNefits aNd risks of MediCiNes UsiNg a 
disCrete ChoiCe exPeriMeNt
Beyer A1, Hoekstra T1, Selivanova A2, Kingma B1, Hillege JL1, Krabbe PF2
1University Medical Center Groningen, Groningen, The Netherlands, 2University of Groningen, 
University Medical Center Groningen, Groningen, The Netherlands
objeCtives: Differences in preferences for treatment outcomes are known to exist 
among patients and healthcare professionals, but rarely are data available that 
include the preferences of medical regulators. Methods: Discrete choice (DCE) 
methodology was applied via an online questionnaire among patients and experts 
(HCPs, European medical assessors) in three disease areas (atrial fibrillation (AF), 
breast cancer (BC) and type II diabetes (DB)) in the United Kingdom, France and 
the Netherlands. Selection of the attributes was made via focus group question-
naires among 150 patients in each disease area. Data for the required number of 
drug scenarios were compiled from existing medicines for the disease areas and 
participants were asked to choose the drug they preferred. An alternative-specific 
conditional logit model was used to evaluate the choices made for each pair of 
scenarios. Results: Data were collected from 1288 patients: 205 AF; 531 BC; 552 
DB. Data for HCPs and medical assessors present the expert view: 89 AF; 211 BC; 122 
DB. Atrial fibrillation patients chose the prevention of stroke as the most important 
attribute while for experts fatal bleeding was the most important attribute; all other 
attributes were given the same order of importance by both groups. For diabetes, 
both patients and experts indicated preventing cardiac disorders as most important 
attribute of a treatment. However, the order of the remaining attributes differed. For 
breast cancer, the order of importance of all the attributes was the same for patients 
and experts. The choices were not explained by demographic characteristics and 
disease severity had no impact on the choices made by patients. ConClusions: 
With the exception of breast cancer, the view that patients and experts have dif-
ferent preferences for treatment outcomes continues to be supported by this data. 
There may exist a chronic/acute illness axis that may differentiate the preferences 
between experts and patients.
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objeCtives: Recent initiatives within Europe to increase the involvement of 
patients in the regulation of medicines are positive actions. However, is there a 
shared view among European patients on the favorable and unfavorable outcomes 
of medicines? This study aims to assess differences in preferences for treatment 
outcomes across three countries in Europe. Methods: Data were collected via web-
questionnaires from patients diagnosed with atrial fibrillation (AF), breast cancer 
(BC) and type II diabetes (DB)) in the United Kingdom, France and the Netherlands. A 
panel of physicians, epidemiologists, and healthcare researchers reviewed favorable 
and unfavorable outcomes of current treatments and compiled a list of treatment 
outcomes. Patients were asked to rank by order of importance the treatment out-
comes specific to their area of disease. Results: A total of 454 patients provided 
data: age 20-75 years; predominantly female for DB and AF and all female for BC. 
AF patients across all countries ranked reduction in fatal ischemic stroke as the 
most favorable treatment outcome and fatal hemorrhage as the most unfavorable 
outcome. Dutch and British BC patients ranked overall survival as most favorable, 
while French BC patients selected health related quality of life. All BC patients 
selected cardiotoxicity as the most unfavorable outcome. Dutch and French DB 
patients ranked decreased fasting glucose as most favorable outcome, while British 
DB patients were divided between reduction in weight, reduction in hemoglobin and 
changes in blood pressure. Dutch and British DB patients ranked congestive heart 
failure as the most unfavorable outcome, while French patients selected hypogly-
cemia. ConClusions: Patient differences, as determined by demographics and 
disease characteristics, are commonplace in medical research; however exploration 
of country and regional differences in values and preferences among patients are 
less common and should be included in any research activity aimed at elucidating 
the representative patient voice for Europe.
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objeCtives: Novel treatments for advanced melanoma have been developed with dif-
fering levels of effectiveness, safety, cost, and route of administration. Understanding 
the preferences among these attributes between patients and physicians is necessary 
for quality treatment and shared decision making. In health care, Discrete Choice 
Experiment (DCE) is one of the recommended tools for eliciting treatment preferences 
by reflecting different perspectives and the trade-off between attributes. The objective 
of this study is to measure patient and physician preferences by conducting a DCE 
for advanced melanoma treatments with a special focus on immunotherapy and 
objeCtives: To determine the direct out-of-pocket expenses (co-payments) 
and overall satisfaction among patients enrolled in the Z Benefits for breast 
cancer. Methods: The database of paid claims was the sampling frame of the 
study. Participants were identified and trained data collectors conducted patient 
interviews using a pre-tested semi-structured survey tool. Participants signed an 
informed consent for an interview, audio and video documentation of feedbacks. 
Clinical data were extracted from medical records while out-of-pocket expenses 
were reviewed from statements of account and receipts of services received. 
Patient satisfaction during surgery, chemotherapy and overall patient satisfaction 
were validated with the satisfaction questionnaires submitted by the contracted 
hospitals. Results: A total of 80 claims for breast cancer using the Z benefit 
package were identified from July 2012 to August 2014 from five contracted hos-
pitals. Respondents underwent modified radical mastectomy with 50 patients 
receiving standard adjuvant chemotherapy. During hospital confinement, 41 
patients purchased medicines outside the hospital pharmacy. The overall aver-
age out-of-pocket expense was at Php 3600 (US$ 80). The average out-of-pocket 
expense was Php 4000 (US $ 89) for medicines, Php 1600 (US $ 36) for laboratory 
tests and Php 4200 (US $ 93) for professional fees which are within the allowed co-
payment limits. Patient satisfaction was generally good with satisfaction rates of 
98% and 92% for surgery and chemotherapy services, respectively. ConClusions: 
The overall patient satisfaction is favourable but there were still out-of-pocket 
expenses for medicines, laboratory tests and professional fees amounting to an 
average of Php 3,600 (US$80).
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objeCtives: To compare patient satisfaction with intravenous rituximab (RIV) 
versus subcutaneous rituximab (RSC) using the reliable and validated instrument, 
Rituximab Administration Satisfaction Questionnaire (RASQ). Methods: PrefMab 
(NCT01724021) is a randomized, open-label, crossover Phase IIIb study in patients 
with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma (grade 
1–3a). Patients received chemotherapy (6–8 cycles CHOP [cyclophosphamide, doxo-
rubicin, vincristine, prednisone], CVP [cyclophosphamide, vincristine, prednisone], 
or bendamustine) plus 8 cycles of rituximab; Arm A: 1 cycle RIV (375 mg/m2) and 
3 cycles RSC (1400 mg) then 4 cycles RIV; Arm B: 4 cycles RIV (375 mg/m2) then 
4 cycles RSC (1400 mg). The general Cancer Therapy Satisfaction Questionnaire 
(CTSQ), and RASQ, were conducted at cycles 4 and 8; domains for both question-
naires were scored 0 (least)–100 (best). Adverse events were monitored through-
out. Results: At the primary data cut, January 19, 2015, the intent-to-treat 
population was: Arm A, n= 372; Arm B, n= 371. Median age was 60 years (range 
18–80). Baseline characteristics were balanced between arms. Overall median 
CTSQ scores with RSC and RIV were similar for all domains: expectations, side 
effects, and satisfaction with therapy. Overall median RASQ scores were higher 
for RSC versus RIV for psychological impact (88 vs 80), impact on daily living (83 
vs 58), convenience (83 vs 58), and satisfaction with therapy (88 vs 75), with no 
difference for physical impact. Overall, most patients considered time required 
to administer R was ‘just right’ (88% SC vs 56% IV), and they had ’more than 
enough time’ to discuss concerns with their doctors/nurses (79% SC vs 79% IV). 
Treatment sequence did not impact CTSQ or RASQ scores. No new safety signals 
were detected. ConClusions: Patient satisfaction with R-chemotherapy was 
comparable for RSC and RIV. However, rituximab-specific satisfaction measured 
by RASQ was generally greater with RSC than RIV.
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objeCtives: The aim of this study was to better understand the impact of 
advanced NSCLC and its treatment on the quality of life and experience of 
patients, in order to inform the design and inclusion of outcome assessments in 
clinical trials. Methods: Face-to-face, qualitative, semi-structured interviews were 
conducted with 20 UK participants with advanced NSCLC. Interviews explored par-
ticipants’ experiences of aNSCLC and the treatment they received. Open-ended 
questioning (facilitating spontaneous reporting), was followed by focused questions 
to further investigate important themes. Creative methods including an impact rat-
ing ladder and timeline task were used to elicit content. Verbatim transcripts were 
analyzed using a data-driven, thematic analysis approach. Results: Participants 
experienced considerable burden from symptoms and treatment-related side effects 
(e.g. breathlessness, nausea), which left them unable to participate in activities 
of daily living such as housework, shopping or going outside. However, partici-
pants reported that the emotional impact on them and their families (e.g. worry, 
sadness and frustration) had the biggest negative impact on their lives. Almost 
all participants were highly satisfied with their treatment and care, but time lost 
to receiving and recovering from treatment was commonly reported. Efficiency, 
communication and practical and emotional support were aspects of care valued 
most by participants. The majority of participants asked said they would prioritise 
